Matching articles for "Correction"
Issue 1310 · April 20, 2009 Free
Correction: Vancomycin Dosing and Monitoring

(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):32
(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the infecting organism is ≥2 mg/L, not >2 mg/L .
Issue 1303 · January 12, 2009 Free
Correction: CT Colonography

(Med Lett Drugs Ther 2008; 50:94) In Table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively. In the conclusion, CT colonography should be…

Med Lett Drugs Ther. 2009 Jan 12; 51(1303):4
(Med Lett Drugs Ther 2008; 50:94) In Table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively. In the conclusion, CT colonography should be changed to "less invasive" rather than "noninvasive".
Issue 1301 · December 15, 2008 Free
Correction: CT Colonography

(Med Lett Drugs Ther 2008; 50:94) In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively.

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):97-100
(Med Lett Drugs Ther 2008; 50:94) In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively.
Issue 1300 · December 1, 2008 Free
Correction: Bendamustine (Treanda) for CLL and NHL

(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).

Med Lett Drugs Ther. 2008 Dec 1; 50(1300):96
(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).
Issue 1292 · August 11, 2008 Free
Correction: The EarCheck Middle Ear Monitor

The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic…

Med Lett Drugs Ther. 2008 Aug 11; 50(1292):64
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
Issue 1287 · June 2, 2008 Free
Correction: Natalizumab (Tysabri) for Crohn's Disease

The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement:…

Med Lett Drugs Ther. 2008 Jun 2; 50(1287):44
The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement: "post-marketing hepatotoxicity, sometimes fatal or requiring liver transplantation, has occurred." Actually, no fatal hepatotoxicity or liver transplantation has been reported to date. The FDA warning about post-marketing hepatotoxicity with Tysabri that was the basis for our statement said: "The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is recognized as an important predictor of severe liver injury that may lead to [emphasis added] death or the need for a liver transplant in some patients." Also, in the last sentence of the Conclusion, we should have said: "Because of the risk of serious hepatic toxicity and the rare but even more serious risk of developing progressive multifocal leukoencephalopathy, it should be used only in patients who have not responded to other drugs, including a TNF inhibitor." The italicized words should be substituted for "it is FDA-approved for use." Download: U.S. English
Issue 1276 · December 17, 2007 Free
Correction: Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures

On page 100 of the article " Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures ", under the section Highest-Risk Procedures, the word "rubber" should have been omitted. Placement of…

Med Lett Drugs Ther. 2007 Dec 17; 49(1276):104
On page 100 of the article " Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures ", under the section Highest-Risk Procedures, the word "rubber" should have been omitted. Placement of orthodontic rubber bands is not a highest-risk procedure that justifies prophylaxis; placement of orthodontic (metal) bands is. An orthodontic band is a metal ring that surrounds the tooth and is pressed into place causing movement in closely-spaced teeth and sometimes bleeding when the bands are placed close to the gumline.
Issue 1271 · October 8, 2007 Free
Correction: Low Dose Transdermal Estrogens

The Medical Letter article ( Med Lett Drugs Ther 2007; 49:71 ) on Low-Dose Transdermal Estrogens said that Elestrin has been marketed in Europe since 1976. Actually it is EstroGel (Ascend Therapeutics), a…

Med Lett Drugs Ther. 2007 Oct 8; 49(1271):84
The Medical Letter article ( Med Lett Drugs Ther 2007; 49:71 ) on Low-Dose Transdermal Estrogens said that Elestrin has been marketed in Europe since 1976. Actually it is EstroGel (Ascend Therapeutics), a similar product, that has been available in Europe since 1976.
Issue 1019 · January 30, 1998
Arbutamine for Stress Testing

Myocardial perfusion imaging and stress echocardiography in patients who cannot exercise may require use of drugs. Arbutamine ( GenESA - Gensia Automedics), a potent synthetic sympathomimetic, has recently…

Med Lett Drugs Ther. 1998 Jan 30; 40(1019):19-20
Myocardial perfusion imaging and stress echocardiography in patients who cannot exercise may require use of drugs. Arbutamine ( GenESA - Gensia Automedics), a potent synthetic sympathomimetic, has recently been approved by the FDA for use with a computerized drug-delivery system in pharmacologic stress testing.
Issue 928 · August 5, 1994
Rocuronium - A New Neuromuscular Blocker

Rocuronium bromide ( Zemuron - Organon), a new short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use. It is being promoted particularly…

Med Lett Drugs Ther. 1994 Aug 5; 36(928):71-2
Rocuronium bromide ( Zemuron - Organon), a new short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use. It is being promoted particularly for use in rapid endotracheal intubation.
Issue 923 · May 27, 1994
EDTA Chelation Therapy for Atherosclerotic Cardiovascular Disease

The Medical Letter continues to receive inquiries about the value of edetate disodium (EDTA) chelation therapy for cardiovascular disease. The last Medical Letter article on this subject was published in 1981…

Med Lett Drugs Ther. 1994 May 27; 36(923):48
The Medical Letter continues to receive inquiries about the value of edetate disodium (EDTA) chelation therapy for cardiovascular disease. The last Medical Letter article on this subject was published in 1981 (volume 23, page 51). Some authors have estimated that more than 500,000 people receive this form of treatment each year (MT Grier and DG Meyers, Ann Pharmacother, 27:1504, Dec 1993).
Issue 908 · October 29, 1993
Drugs for Tuberculosis

The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the…

Med Lett Drugs Ther. 1993 Oct 29; 35(908):99-102
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).
Issue 907 · October 15, 1993
Masoprocol for Multiple Actinic Keratoses

Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.

Med Lett Drugs Ther. 1993 Oct 15; 35(907):97-8
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
Issue 884 · November 27, 1992
Topical Treatment for Bacterial Vaginosis

A 0.75% vaginal gel formulation of metronidazole ( MetroGel-Vaginal - Curatek) and a 2% vaginal cream formulation of clindamycin phosphate ( Cleocin - Upjohn) were recently approved by the US Food and Drug…

Med Lett Drugs Ther. 1992 Nov 27; 34(884):109-10
A 0.75% vaginal gel formulation of metronidazole ( MetroGel-Vaginal - Curatek) and a 2% vaginal cream formulation of clindamycin phosphate ( Cleocin - Upjohn) were recently approved by the US Food and Drug Administration for treatment of bacterial vaginosis. Seven days' treatment with oral metronidazole, 500 mg b.i.d., has been the usual treatment for this condition, with oral clindamycin, 300 mg b.i.d., as an alternative (JL Thomason et al, Am J Obstet Gynecol, 165:1210, 1991).
Issue 868 · April 17, 1992
Nabumetone - A New Nsaid

Nabumetone ( Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis.…

Med Lett Drugs Ther. 1992 Apr 17; 34(868):38-40
Nabumetone ( Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987. The manufacturer claims that nabumetone is as effective as other NSAIDs and causes a relatively low incidence of peptic ulcers.
Issue 849 · July 26, 1991
Doxacurium

Doxacurium ( Nuromax - Burroughs Wellcome), a new, long-acting, nondepolarizing neuromuscular blocking agent, is now available in the USA for use as a skeletal muscle relaxant during general anesthesia and for…

Med Lett Drugs Ther. 1991 Jul 26; 33(849):73-4
Doxacurium ( Nuromax - Burroughs Wellcome), a new, long-acting, nondepolarizing neuromuscular blocking agent, is now available in the USA for use as a skeletal muscle relaxant during general anesthesia and for endotracheal intubation. Although small decreases in heart rate and mean arterial pressure occur in some patients who receive doxacurium, clinical studies have found no adverse cardiovascular effects in patients with heart disease receiving up to three times the usual effective dose (CM Stoops et al, Anesthesiology, 69:365, 1988; DJ Murray et al, Anesthesiology, 69:472, 1988; RS Emmott et al, Br J Anaesth, 65:480, 1990). As with pipecuronium, which it closely resembles in activity, the duration of block is prolonged in patients with renal failure (JN Cashman et al, Br J Anaesth, 64:186, 1990; DR Cook et al, Anesth Analg, 72:145, 1991).
Issue 847 · June 28, 1991
Ondansentron To Prevent Vomiting After Cancer Chemotherapy

Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An…

Med Lett Drugs Ther. 1991 Jun 28; 33(847):63-4
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.
Issue 831 · November 16, 1990
Olsalazine

Olsalazine sodium ( Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain…

Med Lett Drugs Ther. 1990 Nov 16; 32(831):105-6
Olsalazine sodium ( Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine ( Azulfidine ; and others).
Issue 796 · July 14, 1989
Octreotide - A Synthetic Somatostatin

Octreotide acetate ( Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients…

Med Lett Drugs Ther. 1989 Jul 14; 31(796):66-8
Octreotide acetate ( Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas (vasoactive intestinal peptide-secreting tumors).
Issue 792 · May 19, 1989
Nimodipine for Cerebral Vasospasm Subarachnoid Hemorrhage

Cerebral arterial spasm frequently causes ischemic neurological damage after subarachnoid hemorrhage from a ruptured intracranial aneurysm. Nimodipine ( Nimotop - Miles), a 1,4-dihydropyridine calcium-entry…

Med Lett Drugs Ther. 1989 May 19; 31(792):47-8
Cerebral arterial spasm frequently causes ischemic neurological damage after subarachnoid hemorrhage from a ruptured intracranial aneurysm. Nimodipine ( Nimotop - Miles), a 1,4-dihydropyridine calcium-entry blocker, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of such patients; an intravenous preparation is available only for investigational use.